On Dec. 12, the U.S. House is set to vote on H.R. 3, a bill that will have catastrophic consequences for patients and California’s life sciences sector. Learn why in this STAT News op-ed from CLSA CEO Mike Guerra.
CLSA’s HR 3 impact study was featured in this high-profile STAT News article, highlighting the impact that the drug pricing proposal (HR 3) would have on small and emerging biotechnology companies in California.
California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.
California Life Sciences Association (CLSA) was recently featured in the San Diego Business Journal commenting on changes by California regulatory agencies that impact Association health plans, including CLSA’s Benefits Advantage Trust plan for small businesses.
California Life Sciences Association President & CEO Mike Guerra was recently profiled by the San Francisco Business Times. Learn about the association’s priorities, Mike’s background and more.
California Life Sciences Association was recently featured in BioSpace regarding a multi-state life sciences coalition letter it led, urging Congressional leaders to reject flawed foreign price controls proposals in legislation to lower drug prices.
Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
CLSA President & CEO Mike Guerra was recently featured in the San Diego Union-Tribune commenting on employment trends in California’s life sciences sector.
“We all agree that drug prices are high, but a proposal before the Legislature would make that situation worse, even as it seeks to solve the problem.” Read more about AB 824 in CalMatters.
CLSA Board Member Wendye Robbins, MD, President & CEO of Blade Therapeutics, pens an op-ed in the San Francisco Chronicle, urging the Legislature to make key changes to Assembly Bill 824, priority legislation for CLSA that seeks to prohibit generic drug manufacturers from seeking patent settlement agreements.